Results 51 to 60 of about 327,565 (313)

Rewriting the dendritic cell code in cancer—from subset identity to immunotherapeutic design

open access: yesFEBS Letters, EarlyView.
Dendritic cells (DCs) play central roles in cancer immunity but are often subverted by the tumor microenvironment. This review explores the diversity of DC subsets, their functional plasticity, and emerging therapeutic strategies to reprogram DCs for enhanced antitumor responses, including vaccines, in vivo targeting, and DC‐based immunotherapies ...
Estevão Carlos Silva Barcelos   +3 more
wiley   +1 more source

From omics to AI—mapping the pathogenic pathways in type 2 diabetes

open access: yesFEBS Letters, EarlyView.
Integrating multi‐omics data with AI‐based modelling (unsupervised and supervised machine learning) identify optimal patient clusters, informing AI‐driven accurate risk stratification. Digital twins simulate individual trajectories in real time, guiding precision medicine by matching patients to targeted therapies.
Siobhán O'Sullivan   +2 more
wiley   +1 more source

Mycobacterium tuberculosis sulfurtransferase SseA is activated by its neighboring gene product Rv3284

open access: yesFEBS Letters, EarlyView.
Tuberculosis remains a global health challenge and new therapeutic targets are required. Here, we characterized SseA, a sulfurtransferase from Mycobacterium tuberculosis involved in macrophage infection, and its interaction with the newly identified protein SufEMtb that activates SseA enzymatic activity.
Giulia Di Napoli   +10 more
wiley   +1 more source

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression

open access: yesMolecular Oncology, EarlyView.
Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park   +6 more
wiley   +1 more source

Plasmon Sensitized Heterojunction 2D Ultrathin Ag/AgI-δ-Bi2O3 for Enhanced Photocatalytic Nitrogen Fixation

open access: yesNanomaterials, 2019
A novel 2D ultrathin Ag/AgI-δ-Bi2O3 photocatalyst was constructed by a facile hydrothermal and in situ photodeposition method, which presented a uniform nanosheet structure with an average height of 6 nm.
Xiaoming Gao   +3 more
doaj   +1 more source

TOMM20 as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis

open access: yesMolecular Oncology, EarlyView.
TOMM20 increases cancer aggressiveness by maintaining a reduced state with increased NADH and NADPH levels, oxidative phosphorylation (OXPHOS), and apoptosis resistance while reducing reactive oxygen species (ROS) levels. Conversely, CRISPR‐Cas9 knockdown of TOMM20 alters these cancer‐aggressive traits.
Ranakul Islam   +9 more
wiley   +1 more source

Computational Fluid Dynamics Applied To Chemical Reaction Engineering [PDF]

open access: yes, 1998
In this paper a brief review will be presented on the application of Computational Fluid Dynamics (CFD) to the field of Chemical Reaction Engineering (CRE) with emphasis on multiphase flow due to its practical importance. The theoretical framework will be briefly discussed together with available computational strategies for dispersed multiphase flows.
Jam Hans Kuipers, van Wpm Wim Swaaij
openaire   +4 more sources

Transcriptome‐wide analysis of circRNA and RBP profiles and their molecular relevance for GBM

open access: yesMolecular Oncology, EarlyView.
CircRNAs are differentially expressed in glioblastoma primary tumors and might serve as therapeutic targets and diagnostic markers. The investigation of circRNA and RNA‐binding proteins (RBPs) interactions shows that distinct RBPs play a role in circRNA biogenesis and function.
Julia Latowska‐Łysiak   +14 more
wiley   +1 more source

Targeting the MDM2‐MDM4 interaction interface reveals an otherwise therapeutically active wild‐type p53 in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
This study investigates an alternative approach to reactivating the oncosuppressor p53 in cancer. A short peptide targeting the association of the two p53 inhibitors, MDM2 and MDM4, induces an otherwise therapeutically active p53 with unique features that promote cell death and potentially reduce toxicity towards proliferating nontumor cells.
Sonia Valentini   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy